/MCK
McKesson Corporation
MCK • NYSEMCK • NYSE • Healthcare
$978.71-1.71%-16.98
$978.71-1.71%(-16.98)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
51Neutral
Risk
100Low Risk
Momentum
95Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
3.5%▼0.5pp
Revenue after COGS
Operating
1.2%▼0.1pp
After operating expenses
Net
0.9%▼0.1pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
26.0
Price vs earnings
EV/EBITDA
16.7
Enterprise value
FCF Yield
6.1%
Cash generation
Earnings Yield
3.8%
Inverse of P/E
Capital Efficiency
-35
GoAI Quality ScorePoor
ROEReturn on Equity
-158.9%Weak
ROAReturn on Assets
4.4%Fair
ROICReturn on Invested Capital
23.3%Strong
Financial Health
Current RatioWeak
0.90
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
0.32x
Debt repayment capacity (<3x)
Income QualityStrong
1.75
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $359.05B | $308.95B | $276.71B | $263.97B | $238.23B |
| Gross Profit | $12.48B | $12.20B | $11.87B | $12.65B | $11.58B |
| Gross Margin | 3.5% | 3.9% | 4.3% | 4.8% | 4.9% |
| Operating Income | $4.37B | $3.93B | $4.45B | $2.72B | $3.51B |
| Net Income | $3.29B | $3.00B | $3.56B | $1.11B | -$4.54B |
| Net Margin | 0.9% | 1.0% | 1.3% | 0.4% | -1.9% |
| EPS | $25.86 | $22.54 | $25.23 | $7.31 | -$27.02 |
Average Price Target
$967.33▼ 1.2% Downside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for McKesson Corporation, the average price target is $967.33, with a high forecast of $1050.00 and a low forecast of $900.00. The average price target represents a 1.2% decrease from the current price of $978.71.
Highest
$1050.00
Average
$967.33
Lowest
$900.00
Rating Distribution
Strong Buy
1
3%
Buy
24
77%
Hold
6
19%
Sell
0
0%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Barclays● Maintain
Overweight
2026-02-18JP Morgan● Maintain
Overweight
2026-02-10TD Cowen● Maintain
Buy
2026-02-05Wells Fargo● Maintain
Equal Weight
2026-02-05Mizuho● Maintain
Neutral
2026-02-05Wells Fargo● Maintain
Equal Weight
2025-11-10Morgan Stanley● Maintain
Overweight
2025-11-06Baird● Maintain
Outperform
2025-11-06UBS● Maintain
Buy
2025-11-06UBS● Maintain
Buy
2025-10-27Earnings History & Surprises
BEAT RATE
78%
Last 18 quarters
AVG SURPRISE
+6.4%
EPS vs Estimate
BEATS / MISSES
14/4
Last 18 quarters
LATEST EPS
$9.34
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+1.9%
$9.34 vs $9.17
Q4 '25
+9.2%
$9.86 vs $9.03
Q3 '25
+1.5%
$8.26 vs $8.14
Q2 '25
+3.0%
$10.12 vs $9.83
Q1 '25
-6.6%
$8.03 vs $8.60
Q4 '24
+2.8%
$7.07 vs $6.88
Q3 '24
+9.3%
$7.88 vs $7.21
Q2 '24
-2.5%
$6.18 vs $6.34
Q1 '24
+9.9%
$7.74 vs $7.04
Q4 '23
+1.3%
$6.23 vs $6.15
Q3 '23
+23.9%
$7.27 vs $5.87
Q2 '23
+0.3%
$7.19 vs $7.17
No investor questions available.
Latest News
No news available